Opus Genetics (IRD) Non Operating Income (2010 - 2020)
Opus Genetics (IRD) posted quarterly Non Operating Income of $102411.0 for Q3 2020, down 68.14% year-over-year from $321394.0 in Q4 2019, and up 162.96% quarter-over-quarter from -$162660.0 in Q2 2020.
Opus Genetics (IRD) Non Operating Income (2010 - 2020) Analysis & Trends
Opus Genetics (IRD) has reported Non Operating Income for 11 consecutive years, with $102411.0 the latest figure, recorded in Q3 2020.
- In Q3 2020, Non Operating Income fell 68.14% year-over-year to $102411.0; the TTM figure through Sep 2020 stood at $55063.0 (down 98.72% YoY), while the FY2019 annual figure was $2.6 million, down 58.19% from the prior year.
- Non Operating Income rose to $102411.0 in Q3 2020 per IRD's latest filing, from -$162660.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $5.2 million in Q2 2017 and bottomed at -$17.7 million in Q1 2017.
- Historically, Non Operating Income has averaged $412144.4 across 5 years, with a median of $850579.0 in 2016.
- Annual changes were most pronounced in 2016 — Non Operating Income soared 389.69% — and 2017, when it slumped 2569.83%.
- Opus Genetics' Non Operating Income stood at $3.4 million in 2016, then slumped by 61.52% to $1.3 million in 2017, then soared by 41.67% to $1.8 million in 2018, then tumbled by 92.47% to $139286.0 in 2019, then declined by 26.47% to $102411.0 in 2020.
- Business Quant data shows IRD's Non Operating Income at $102411.0 in Q3 2020, -$162660.0 in Q2 2020, and -$23974.0 in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Opus Genetics | 298.36 Mn | 209.55 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 102,411.00 |
| Jun 30, 2020 | -162,660.00 |
| Mar 31, 2020 | -23,974.00 |
| Dec 31, 2019 | 139,286.00 |
| Sep 30, 2019 | 321,394.00 |
| Jun 30, 2019 | 524,133.00 |
| Mar 31, 2019 | 1.59 Mn |
| Dec 31, 2018 | 1.85 Mn |
| Sep 30, 2018 | -654,912.00 |
| Jun 30, 2018 | 1.16 Mn |
| Mar 31, 2018 | 3.81 Mn |
| Dec 31, 2017 | 1.31 Mn |
| Sep 30, 2017 | 3.18 Mn |
| Jun 30, 2017 | 5.23 Mn |
| Mar 31, 2017 | -17.66 Mn |
| Dec 31, 2016 | 3.39 Mn |
| Sep 30, 2016 | 850,579.00 |
| Jun 30, 2016 | 2.15 Mn |
| Mar 31, 2016 | 714,939.00 |
| Dec 31, 2015 | 1.52 Mn |